WallStreetZenWallStreetZen

NASDAQ: CUTR
Cutera Inc Stock Forecast, Predictions & Price Target

Analyst price target for CUTR

Based on 1 analyst offering 12 month price targets for Cutera Inc.
Min Forecast
$10.00+385.44%
Avg Forecast
$10.00+385.44%
Max Forecast
$10.00+385.44%

Should I buy or sell CUTR stock?

Based on 1 analyst offering ratings for Cutera Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CUTR stock forecasts and price targets.

CUTR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-22

1 of 1

Forecast return on equity

Is CUTR forecast to generate an efficient return?
Company
N/A
Industry
-0.02%
Market
17.33%

Forecast return on assets

Is CUTR forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.02%

CUTR revenue forecast

What is CUTR's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$162.3M-17.44%
Avg 2 year Forecast
$173.0M-12.02%
Avg 3 year Forecast
$187.6M-4.6%
CUTR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CUTR revenue growth forecast

How is CUTR forecast to perform vs Medical Devices companies and vs the US market?
Company
-5.87%
Industry
8.37%
Market
9.4%
CUTR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CUTR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CUTR vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
CUTR$2.06$10.00+385.44%Strong Buy
ECOR$6.84$15.00+119.30%Buy
ICAD$1.58N/AN/A
LFWD$4.72$13.00+175.42%Buy
XAIR$1.11$8.00+623.98%Strong Buy

Cutera Stock Forecast FAQ

Is Cutera Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CUTR) stock is to Strong Buy CUTR stock.

Out of 1 analyst, 1 (100%) are recommending CUTR as a Strong Buy, 0 (0%) are recommending CUTR as a Buy, 0 (0%) are recommending CUTR as a Hold, 0 (0%) are recommending CUTR as a Sell, and 0 (0%) are recommending CUTR as a Strong Sell.

If you're new to stock investing, here's how to buy Cutera stock.

What is CUTR's revenue growth forecast for 2024-2026?

(NASDAQ: CUTR) Cutera's forecast annual revenue growth rate of -5.87% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.4%.

Cutera's revenue in 2024 is $196,636,000.On average, 3 Wall Street analysts forecast CUTR's revenue for 2024 to be $3,258,363,560, with the lowest CUTR revenue forecast at $3,233,614,666, and the highest CUTR revenue forecast at $3,273,758,858. On average, 3 Wall Street analysts forecast CUTR's revenue for 2025 to be $3,472,472,608, with the lowest CUTR revenue forecast at $3,309,888,630, and the highest CUTR revenue forecast at $3,621,006,118.

In 2026, CUTR is forecast to generate $3,765,525,210 in revenue, with the lowest revenue forecast at $3,474,479,818 and the highest revenue forecast at $4,056,570,602.

What is CUTR's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: CUTR) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of -0.02%.

What is CUTR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CUTR price target, the average CUTR price target is $10.00, with the highest CUTR stock price forecast at $10.00 and the lowest CUTR stock price forecast at $10.00.

The Wall Street analyst predicted that Cutera's share price could reach $10.00 by Mar 22, 2025. The average Cutera stock price prediction forecasts a potential upside of 385.44% from the current CUTR share price of $2.06.

What is CUTR's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: CUTR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.